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Missense mutations in theWNK4 gene lead to the development of familial hyperkalemic hypertension, a rare form of human
hypertension. It was shown in vitro that WNK4 regulates the surface expression and activity of a number of ion channels and
transporters. The in vivo analysis of wild-type and mutant WNK4 overexpression in transgenic mice models demonstrated
that this serine-threonine kinase controls ion handling in the kidney mainly, and probably exclusively, through the regulation
of the Na-Cl contransporter NCC activity.Familial hyperkalemic hypertension (FHHt),
also called Pseudohypoaldosteronism
type II (PHAII), is a rare autosomal
dominant form of arterial hypertension,
characterized by hypertension, hyperka-
lemia, mild hyperchloremia, and meta-
bolic acidosis despite normal renal glo-
merular filtration (Gordon et al., 1995).
In 2001, the genetic analysis of a few af-
fected families led to the identification of
two new and unsuspected potential reg-
ulators of blood pressure, WNK1 and
WNK4 (Wilson et al., 2001). They belong
to a recently identified family of serine-
threonine kinases, the with no lysine (k)
(WNK) kinase family (Xu et al., 2000). In
addition to the kinase domain, these pro-
teins contain an autoinhibitory domain,
two coiled-coil domains, and three pro-
line-rich domains. WNK4 mutations re-
sponsible for FHHt correspond to amino
acid changes located in small (about
10 amino acids) and highly conserved
sequences, just downstream of the two
coiled-coil domains (Wilson et al., 2001).
Coiled-coil domains being generally de-
scribed as protein-protein interaction
domains, the mutations are supposed to
affect the interaction of WNK4 with its
partners.
The clinical and biological phenotype
of FHHt corresponds to an altered ionic
transport in the renal distal tubule. Af-
fected subjects are highly sensitive to thi-
azide diuretics suggesting a deregulation
of NCC activity, the thiazide-sensitive
sodium-chloride cotransporter. Indeed,
it was shown thatWNK4 inhibits NCC ac-
tivity in Xenopus oocytes by decreasing
its surface expression and that mutated
WNK4 lost this ability to regulate NCC
(Wilson et al., 2003). Other in vitro stud-
ies, in Xenopus oocytes or cultured renal
cells, showed that the regulatory role
of WNK4 extends to the regulation of
a wide range of transport systems ex-
pressed in the distal nephron (Hadchouel
et al., 2006). WNK4 could inhibit theCELL METABOLISM : NOVEMBER 2006activity of the renal apical K+ channel
ROMK, the basolateral isoform of the
Na+-K+-2Cl- cotransporter (NKCC1), the
apical Cl2/HCO3
2 exchanger CFEX and
TRPV4 (Fu et al., 2006), again by de-
creasing their surface expression. Inter-
estingly, FHHt mutants have a stronger
inhibitory effect on ROMK than wild-
type WNK4. Finally, WNK4 was shown
to stimulate the paracellular chloride
transport, via phosphorylation of mem-
bers of the claudin family that encode
tight junction proteins. Taken together,
these studies suggest that WNK4 plays
a new and unsuspected role in the regu-
lation of a number of renal ion trans-
porters and channels. However, this hy-
pothesis and the hierarchy between the
variety of effects shown in vitro awaited
in vivo confirmation. The group of
Richard Lifton very recently published
such an in vivo study and thus provided
the first integrated view of WNK4 role in
ion handling and blood pressure regula-
tion (Lalioti et al., 2006).
The authors demonstrated that over-
expression of a mutant (Q562E) WNK4
(WNK4PHAII transgene) in transgenic
mice reproduces the phenotype ob-
served in FHHt patients, i.e., hyperten-
sion,hyperkalemia,hyperchloremia,met-
abolic acidosis and hypercalciuria. In
contrast, overexpression of a wild-type
WNK4 (WNK4WT transgene) led to
hypotension, hypocalciuria, a modest
reduction in chloremia and a tendency
to hypokalemia. Moreover, the authors
showed that overexpression of WNK4,
wild-type ormutated, had consequences
on the morphology of the distal convo-
luted tubule (DCT) and the surface ex-
pression of NCC. There was a marked
hyperplasia in the DCT accompanied by
increased apical expression of NCC in
mice overexpressing WNK4PHAII and a
marked hypoplasia in those overex-
pressing WNK4WT, similar to that ob-
served in mice lacking NCC (Loffinget al., 2004; Schultheis et al., 1998). How-
ever, there was no change in ROMK
expression in WNK4PHAII mice while
overexpression of WNK4WT led to an
increase in ROMK expression at the api-
cal surface. The impaired regulation of
plasma potassium in these transgenic
animals could therefore be due to altered
ionic cellular concentration in the distal
tubule following variations of NCC activ-
ity rather than to a direct effect of
WNK4 on ROMK (Figure 1).
To test this hypothesis, the authors
used two strategies. They first described
the effect of the WNK4PHAII transgene on
blood pressure level and ion handling in
SLC12A32/2 mice, the SLC12A3 gene
encoding NCC. They showed that kale-
mia was restored to normal. In contrast,
the animals presented a hypochloremia
and a severe hypocalciuria. Moreover,
they were hypotensive, with blood pres-
sure level similar to that of WNK4WT ani-
mals. Finally, DCT morphology remained
as seen in SLC12A32/2 mice, with the
proximal part of the DCT being virtually
eliminated. The phenotype seen in the
Tg(WNK4PHAII)/SLC12A32/2 animals is
therefore similar to that of SLC12A32/2
mice (Loffinget al., 2004;Schultheis et al.,
1998). In parallel, transgenic WNK4PHAII
animals received a short-term treatment
with hydrochlorothiazide, an inhibitor of
NCC, which corrected both the hyperka-
lemia and the hypercalciuria. DCT mor-
phology was not analyzed nor was the
blood pressure measured in these ani-
mals. Finally, the authors showed that
wild-type and mutated WNK4 interact
by coimunoprecipitation, suggesting that
WNK4 mutants probably have a domi-
nant negative effect on the wild-type
protein activity.
Taken together, these transgenic
models indicate that FHHt clinical and
biochemical phenotype is mainly, if not
exclusively, the consequence of a dereg-
ulation of NCC activity. This is particularly335
P R E V I E W SFigure 1. Effect of WNK4 surexpression on ionic transport and morphology of the distal convoluted tubule
A) In physiological conditions, WNK4 regulates the balance between apical and cytoplasmic NCC. Na+-reabsorption is then mediated in part by NCC and in part by
ENaC. The latter creates a lumen-negative potential, which drives K+-secretion by ROMK.
B) When mutant WNK4 is overexpressed, NCC apical expression and activity are increased resulting in a decrease in Na+ reabsorption by ENaC and the concomittant
K+ secretion by ROMK. Moreover, the DCT becomes hyperplasic.
C) In contrast, when wild-type WNK4 is overexpressed, NCC apical expression and activity are decreased, the DCT becomes hypoplasic and Na+ is reabsorbed mainly
by ENaC. The resulting lumen-negative potential causes an increase in K+ secretion by ROMK.interesting in the context of the regulation
of potassium secretion. While in vitro
studies suggested that WNK4 could di-
rectly regulate ROMK surface expression
and activity, these in vivo studies imply
that impaired K+ secretion could result
from a decreased sodium reabsorption
by the epithelial sodium channel ENaC
following increased NCC activity (Fig-
ure 1). From a more general point of
view, this study has very important reper-
cussions for the understanding of water/
salt homeostasis and electrolyte han-
dling by the kidney since it may provide
a response to what the authors call a
‘physiological paradox’. They suggest
that WNK4 could be a determinant of
the choice faced by the kidney between
maximal NaCl reabsorption and K+
secretion in response to aldosterone
secretion and that this determination
could be mediated by the modulation
of NCC activity only. O’Reilly et al. re-
cently described the effect of sodium or336potassium dietary challenges as well as
aldosterone infusion on WNK4 expres-
sion (O’Reilly et al., 2006). Using real-
time PCR and semiquantitative in situ
hybridisation, they showed that WNK4
expression is upregulated when K+ in-
take is increased. In contrast, chronic
aldosterone excess or a low sodium
diet has no effect on WNK4 expression.
This is surprising since these three
challenges induce a hyperaldosteronism.
Lalioti et al. (2006) suggest a role for
angiotensin II in the regulation of WNK4
expression or activity but this hypo-
thesis does not explain why an infusion
of aldosterone has no effect on WNK4
while a high-K+ diet does since AngII
level is similar in both conditions. Deci-
phering the mechanisms by which
these different stimuli regulate WNK4
expression is required to better under-
stand the role played by this kinase in
the coordination of ion handling by the
kidney.Juliette Hadchouel1
and Xavier Jeunemaitre1
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Ataxia telangiectasia (A-T) is a progres-
sive, neurogenerative disease that typi-
cally presents itself in the first decade
with delayed development of motor
skills, including poor balance and slurred
speech. About 20% of patients with A-T
develop cancer, most often acute lym-
phocytic lymphoma or leukemia, and
many are immunodeficient and sensitive
to radiation. A-T may be associated
with varying degrees of insulin resistance
and a relatively mild impairment in glyce-
mic control (Ristow, 2004).
A-T is incurable and at this point there
is not even a good way to slow progres-
sion of the disease. A-T is caused by
mutations in Atm (ataxia telangiectasia
mutated), the gene that encodes ATM
(Savitsky et al., 1995). Over 500 muta-
tions causing A-T have been identified;
most affected individuals are compound
heterozygotes. ATM is a large, modular
protein with a serine/threonine kinase
domain and a binding site for the tumor
suppressor, p53. ATM senses breaks in
double-stranded DNA and coordinates
cell cycle checks prior to repair.
Schneider et al. (2006) examine the re-
lationship between ATM deficiency and
metabolism in mice, looking specifically
at aspects of the metabolic syndrome
such as insulin resistance, adiposity,
blood pressure, circulating cholesterol
and lipid levels, andatherosclerosis.Con-
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vincingdata show that evena50%reduc-
tion in gene dosage and probably protein
concentration affects a large number of
metabolic parameters. Fat mass, blood
pressure, fasting, and postchallenge glu-
cose and insulin concentrationswere ele-
vated, insulin sensitivity was decreased,
and atherosclerotic lesions were more
prominent in Atm2/+ and Atm2/2mice.
These pathophysiological changes
were accompanied by concordant bio-
chemical changes in a variety of tissues
and cell types. For example, decreased
insulin signaling accompanied reduced
ATM activity in muscle, liver, and isolated
macrophages. In aorta, there were de-
creases in p38, AKT, and ERK activities,
but increases in inhibited IRS-1 and
JNK activity, a serine/threonine kinase
that inhibits IRS-1 (Figure 1).
The investigators next took advantage
of an interesting in vitro finding, that the
antimalarial chloroquine stimulates ATM
activity in the absence of DNA strand
breaks (Bakkenist and Kastan, 2003).
They took this a step further by using a
small doseofchloroquine toactivateATM
inmice, which decreased atherosclerotic
lesion area in Apoe2/2 mice and insulin
and glucose levels in ob/ob and db/db
mice. Consistent with ATM as the phar-
macological target, chloroquine treatment
decreased JNK activity in macrophages
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, a protein well known for its roles in the
ular diseases (Schneider et al., 2006). ATM
ith related effects in insulin resistance and
timalarial drug, also activates ATM, which
ndings provide potential new insights into
improved blood pressure and glycemic
control in Atm+/+ but not Atm2/2mice.
It is noteworthy that a 50% reduction in
gene dose inAtm2/+mice significantly af-
fected several metabolic parameters,
and it is undoubtedly important from a
mechanistic viewpoint that many of the
parameters studied in heterozygous and
homozygous mice were equivalently
affected. This is in distinct contrast with
what is seen in patients with A-T, where
both alleles are mutated and heterozy-
gous carriers are unaffected. It is doubtful
that drugs such as chloroquine would
benefit patients with A-T. Heterozygous
carriers do however have an increased
risk for developing certain cancers, most
notably breast cancer (Swift et al., 1987).
These new findings (Schneider et al.,
2006) suggest that drugs such as chloro-
quine that upregulate ATM activity might
provide prophylactic benefit to carriers
by decreasing cancer risk. Of course
this needs to be formally tested, but this
could be important for a substantial por-
tion of the population, as 0.5%–2.0%
are suspected of being carriers.
The increase in metabolic and cardio-
vascular abnormalities seen in Atm2/+
mice predicts a greater than previously
appreciated risk for diabetes, hyperten-
sion, and cardiovascular disease in A-T
family members and other carriers. One
would expect that these individuals too
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